AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Viral structures formed during HIV coreceptor interactions can be targeted by potential HIV vaccines, researchers in the United States report.
"Human immunodeficiency virus (HIV) fusion and entry involves sequential interactions between the viral envelope protein, gp120, cell surface CD4, and a G-protein-coupled coreceptor," explained Anthony L. DeVico and colleagues at the University of Maryland Biotechnology Institute and School of Medicine. "Each interaction creates an intermediate gp120 structure predicted to display distinct antigenic features, including key functional domains for viral entry."
These intermediate gp120 structures are vulnerable to antibody neutralization that fails to affect normal gp120, DeVico and coworkers found.
The researchers studied a model of cell fusion using HeLa cells expressing either HIV Env protein or coreceptors crucial for HIV cell entry. In this model, antibodies targeting the CD4-induced coreceptor binding domain reacted only weakly with Env cells, and this reaction could not be enhanced, they said.
However, antibodies specific to some epitopes outside the coreceptor domain (8F101 and A32) demonstrated strong reactions to Env-expressing cells after 30 minutes in culture. This time frame coincided with the start of cell-cell fusion, study data showed.
The formation of intermediate gp120-CD4-CXCR4 complexes was necessary for 8F101 and A32 antibody binding (Antigenic ...
Source: HighBeam Research, Intermediate Viral Structures May Be Target.(Brief Article)